Meprovanmeprozine

Meprovanmeprozine Brand names, Meprovanmeprozine Analogs

Meprovanmeprozine Brand Names Mixture

No information avaliable

Meprovanmeprozine Chemical_Formula

C₂₀H₂₃NS

Meprovanmeprozine RX_link

No information avaliable

Meprovanmeprozine fda sheet

Meprovanmeprozine msds (material safety sheet)

Meprovanmeprozine Synthesis Reference

No information avaliable

Meprovanmeprozine Molecular Weight

309.469 g/mol

Meprovanmeprozine Melting Point

< 25 ^oC

Meprovanmeprozine H₂O Solubility

Soluble as HCl salt

Meprovanmeprozine State

Liquid

Meprovanmeprozine LogP

5.7

Meprovanmeprozine Dosage Forms

Tablets (oral, 1 mg)

Meprovanmeprozine Indication

Used for the symptomatic treatment of parkinsonism.

Meprovanmeprozine Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Meprovanmeprozine Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Meprovanmeprozine side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Meprovanmeprozine Patient Information

Meprovanmeprozine Organisms Affected

Humans and other mammals